Cabaletta Bio (CABA) News Today $1.19 -0.05 (-4.03%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$1.20 +0.02 (+1.26%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period HC Wainwright Estimates Cabaletta Bio FY2029 EarningsApril 4 at 4:17 AM | americanbankingnews.comCabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of "Buy" by AnalystsCabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) has received a consensus recommendation of "Buy" from the ten research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assiApril 4 at 2:36 AM | marketbeat.comFY2025 EPS Estimates for Cabaletta Bio Boosted by AnalystApril 4 at 2:23 AM | americanbankingnews.comWells Fargo & Company Has Lowered Expectations for Cabaletta Bio (NASDAQ:CABA) Stock PriceWells Fargo & Company dropped their target price on shares of Cabaletta Bio from $6.00 to $3.00 and set an "equal weight" rating for the company in a research report on Tuesday.April 3 at 12:52 PM | marketbeat.comCabaletta Bio's (CABA) "Buy" Rating Reaffirmed at HC WainwrightApril 3 at 3:41 AM | americanbankingnews.comGuggenheim Reiterates Buy Rating for Cabaletta Bio (NASDAQ:CABA)April 3 at 3:41 AM | americanbankingnews.comCabaletta Bio price target lowered to $13 from $26 at StifelApril 2 at 3:07 PM | markets.businessinsider.comCabaletta Bio (NASDAQ:CABA) Receives Buy Rating from GuggenheimGuggenheim reiterated a "buy" rating and issued a $23.00 target price on shares of Cabaletta Bio in a report on Tuesday.April 2 at 11:04 AM | marketbeat.comCabaletta Bio (NASDAQ:CABA) Price Target Lowered to $7.00 at UBS GroupUBS Group reduced their price target on shares of Cabaletta Bio from $10.00 to $7.00 and set a "buy" rating on the stock in a research note on Tuesday.April 2 at 11:04 AM | marketbeat.comCabaletta Bio Reports Strong Clinical Progress and Q4 2024 Financial ResultsApril 2 at 10:06 AM | msn.comCabaletta Bio (NASDAQ:CABA) Price Target Cut to $22.00 by Analysts at Morgan StanleyMorgan Stanley cut their target price on Cabaletta Bio from $30.00 to $22.00 and set an "overweight" rating for the company in a research report on Tuesday.April 2 at 8:44 AM | marketbeat.comCabaletta Bio (NASDAQ:CABA) Posts Earnings Results, Meets ExpectationsCabaletta Bio (NASDAQ:CABA - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.65) EPS for the quarter, meeting the consensus estimate of ($0.65).April 2 at 8:42 AM | marketbeat.comCabaletta Bio's (CABA) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $25.00 target price on shares of Cabaletta Bio in a research report on Tuesday.April 2 at 8:30 AM | marketbeat.comCabaletta Bio (NASDAQ:CABA) Releases Earnings Results, Meets EstimatesCabaletta Bio (NASDAQ:CABA - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.65) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.65).April 2 at 8:26 AM | marketbeat.comMorgan Stanley Has Lowered Expectations for Cabaletta Bio (NASDAQ:CABA) Stock PriceApril 2 at 4:17 AM | americanbankingnews.comCabaletta Bio (NASDAQ:CABA) Price Target Lowered to $3.00 at Wells Fargo & CompanyApril 2 at 2:51 AM | americanbankingnews.comCabaletta Bio Advances T Cell Therapies for Autoimmune DiseasesApril 2 at 12:12 AM | tipranks.comCabaletta Bio price target lowered to $3 from $6 at Wells FargoApril 1 at 6:20 PM | markets.businessinsider.comCabaletta Bio price target lowered to $7 from $10 at UBSApril 1 at 6:20 PM | markets.businessinsider.comCabaletta Bio reports Q4 EPS (65c), consensus (63c)March 31, 2025 | markets.businessinsider.comCabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 31, 2025 | globenewswire.comBIT Capital GmbH Takes $431,000 Position in Cabaletta Bio, Inc. (NASDAQ:CABA)BIT Capital GmbH purchased a new position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 190,000 shares of the company's stock, valuedMarch 28, 2025 | marketbeat.comCellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ PlatformMarch 19, 2025 | finance.yahoo.comCabaletta Bio (CABA) to Release Quarterly Earnings on ThursdayCabaletta Bio (NASDAQ:CABA) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 18, 2025 | marketbeat.comCabaletta Bio (CABA) Projected to Post Earnings on ThursdayCabaletta Bio (NASDAQ:CABA) will be releasing earnings before the market opens on Thursday, March 20, Financial Modeling Prep reports.March 13, 2025 | marketbeat.comBrokerages Set Cabaletta Bio, Inc. (NASDAQ:CABA) PT at $22.71Shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) have been given a consensus rating of "Buy" by the eight analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, six have assigned a buy reMarch 12, 2025 | marketbeat.comCabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Buy" by AnalystsCabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) has been given a consensus recommendation of "Buy" by the eight research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, six have issued a buy recommendationMarch 9, 2025 | marketbeat.comCabaletta Bio to Present at TD Cowen 45th Annual Health Care ConferenceFebruary 27, 2025 | msn.comCabaletta Bio to Participate in the TD Cowen 45th Annual Health Care ConferenceFebruary 26, 2025 | globenewswire.comCabaletta Bio (NASDAQ:CABA) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $25.00 price target on shares of Cabaletta Bio in a research report on Tuesday.February 19, 2025 | marketbeat.comCabaletta Bio Reveals Promising Clinical Data for Autoimmune TherapyFebruary 19, 2025 | msn.comCabaletta Bio’s rese-cel shows efficacy in clinical studiesFebruary 19, 2025 | markets.businessinsider.comUPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific MeetingsFebruary 18, 2025 | globenewswire.comCabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific MeetingsFebruary 18, 2025 | globenewswire.comCabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of "Buy" from BrokeragesCabaletta Bio, Inc. (NASDAQ:CABA - Get Free Report) has been assigned a consensus recommendation of "Buy" from the eight analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating aFebruary 12, 2025 | marketbeat.comCabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific ConferencesFebruary 11, 2025 | msn.comCabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in FebruaryFebruary 11, 2025 | globenewswire.comCabaletta Bio, Inc. (NASDAQ:CABA) Shares Sold by Jennison Associates LLCJennison Associates LLC reduced its stake in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 55.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,512,053 shares of the company's stock after selling 3,120,628 shFebruary 6, 2025 | marketbeat.comCabaletta Bio to Present at Guggenheim’s SMID Cap Biotech ConferenceJanuary 31, 2025 | msn.comCabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech ConferenceJanuary 29, 2025 | markets.businessinsider.comCabaletta Bio to Participate in Guggenheim's SMID Cap Biotech ConferenceJanuary 29, 2025 | globenewswire.comCabaletta Bio, Inc. (NASDAQ:CABA) Holdings Decreased by JPMorgan Chase & Co.JPMorgan Chase & Co. cut its position in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) by 70.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 279,954 shares of the company's stock after selling 676,735 sJanuary 25, 2025 | marketbeat.comCantor Fitzgerald Comments on Cabaletta Bio FY2025 EarningsCabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Cabaletta Bio in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings per share of ($2.19)January 23, 2025 | marketbeat.comCabaletta Bio's (CABA) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $25.00 price objective on shares of Cabaletta Bio in a research report on Friday.January 18, 2025 | marketbeat.comCabaletta Bio stock maintain buy rating on trial progressJanuary 17, 2025 | msn.comCabaletta Bio: Advancing Clinical Trials and Strategic Positioning Justify Buy RatingJanuary 17, 2025 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Cabaletta Bio (NASDAQ:CABA)HC Wainwright reiterated a "buy" rating and issued a $25.00 price target on shares of Cabaletta Bio in a research report on Friday.January 17, 2025 | marketbeat.comCabaletta Bio Advances Autoimmune Therapy, Sets Strategic Goals for 2025January 17, 2025 | msn.comWilliam Blair Remains a Buy on Cabaletta Bio (CABA)January 14, 2025 | markets.businessinsider.comCabaletta Bio announces strategic priorities, anticipated milestones for 2025January 14, 2025 | markets.businessinsider.com Remove Ads Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address CABA Media Mentions By Week CABA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CABA News Sentiment▼0.470.61▲Average Medical News Sentiment CABA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CABA Articles This Week▼343▲CABA Articles Average Week Remove Ads Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TSHA News Today ATYR News Today TKNO News Today CMPX News Today ALMS News Today CMPS News Today IMMP News Today CADL News Today PROK News Today DRUG News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CABA) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
